-
公开(公告)号：US10101341B2
公开(公告)日：2018-10-16
申请号：US14110242
申请日：2012-04-06
申请人： Véronique Bodo , Philippe Moingeon , Julien Bouley , Emmanuel Nony , Hélène Moussu , Karine Jain
发明人： Véronique Bodo , Philippe Moingeon , Julien Bouley , Emmanuel Nony , Hélène Moussu , Karine Jain
摘要： The invention relates to proteins for use as markers for the efficacy of sublingual immunotherapy. In particular, the proteins may be used to predict the responsiveness of a patient to immunotherapy. The invention may find use in selecting patients as suitable candidates for immunotherapy.
-
公开(公告)号：US20140112955A1
公开(公告)日：2014-04-24
申请号：US14110242
申请日：2012-04-06
申请人： Véronique Bodo , Philippe Moingeon , Julien Bouley , Emmanuel Nony , Héléne Moussu , Karine Jain
发明人： Véronique Bodo , Philippe Moingeon , Julien Bouley , Emmanuel Nony , Héléne Moussu , Karine Jain
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/6863 , G01N2333/523 , G01N2333/71 , G01N2333/775 , G01N2333/8128 , G01N2800/24 , G01N2800/52 , G01N2800/60
摘要： The invention relates to proteins for use as a marker for the efficacy of sublingual immunotherapy. In particular, the proteins may be used to predict the responsiveness of a patient to immunotherapy. The invention may find use in selecting patients as suitable candidates for immunotherapy.
摘要翻译： 本发明涉及用作舌下免疫治疗功效的标记物的蛋白质。 特别地，蛋白质可用于预测患者对免疫治疗的反应性。 本发明可用于选择患者作为免疫治疗的合适候选者。
-
3.发明申请METHODS FOR IDENTIFYING DENDRITIC CELL SUBSETS, FOR DETERMINING IF A PATIENT IS DEVELOPING A REGULATORY OR AN EFFECTOR IMMUNE RESPONSE, AND FOR DETERMINING RESPONSE TO IMMUNOTHERAPY 审中-公开用于鉴定感染细胞宿主的方法，用于确定患者是如何开发监管或免疫反应，并确定对免疫应答的反应公开(公告)号：US20140377761A1
公开(公告)日：2014-12-25
申请号：US14343480
申请日：2012-09-05
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6881 , C12Q2600/136 , C12Q2600/158
摘要： The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector T cell response, and methods of determining response to immunotherapy.
摘要翻译： 本发明涉及用于确定树突状细胞是否属于耐受性树突状细胞亚群或效应性树突状细胞亚群的方法，以及用于确定进行免疫治疗的患者和/或已经用疫苗给药的方法正在开发一种 针对调节性T细胞应答或效应T细胞应答的免疫应答以及确定免疫治疗反应的方法。
-
公开(公告)号：US09868770B2
公开(公告)日：2018-01-16
申请号：US13109491
申请日：2011-05-17
申请人： Véronique Bordas , Laetitia Bussieres , Sabi Airouche , Sophie Tourdot , Emmanuel Nony , Philippe Moingeon , Julien Bouley
发明人： Véronique Bordas , Laetitia Bussieres , Sabi Airouche , Sophie Tourdot , Emmanuel Nony , Philippe Moingeon , Julien Bouley
IPC分类号： C07H21/02 , C07H21/04 , C12N1/00 , C12N1/20 , C12N15/00 , C12N15/09 , C12P21/04 , C12P21/06 , C07K14/435 , C12N1/16 , C12P21/00
CPC分类号： C07K14/43531 , C07H21/02 , C07H21/04 , C12N1/00 , C12N1/16 , C12N1/20 , C12N15/00 , C12N15/09 , C12P21/00
摘要： The present invention concerns a method for producing a recombinant Dermatophagoides pteronyssinus 2 protein (rDer p 2), comprising the steps of cultivating a Pichia pastoris yeast strain previously transformed with a rDer p 2 coding sequence, and isolating the rDer p 2 protein from said Pichia pastoris yeast strain. The invention also relates to compositions and kits comprising the rDer p 2 protein for therapeutic or diagnostic use.
-
公开(公告)号：US10190166B2
公开(公告)日：2019-01-29
申请号：US14343480
申请日：2012-09-05
IPC分类号： A61K39/35 , A61K39/36 , C12Q1/68 , G01N33/53 , C12Q1/6881
摘要： The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector T cell response, and methods of determining response to immunotherapy.
-
">
6.发明申请Recombinant Der P 2 Expressed in Pichia Pastoris as a "Natural-Like" Allergen for Immunotherapy and Diagnostic Purposes 有权在巴斯德毕赤酵母中表达的重组Der P 2作为免疫治疗和诊断用途的“天然样”过敏原公开(公告)号：US20110293665A1
公开(公告)日：2011-12-01
申请号：US13109491
申请日：2011-05-17
申请人： Véronique BORDAS , Laetitia Bussieres , Sabi Airouche , Sophie Tourdot , Emmanuel Nony , Philippe Moingeon , Julien Bouley
发明人： Véronique BORDAS , Laetitia Bussieres , Sabi Airouche , Sophie Tourdot , Emmanuel Nony , Philippe Moingeon , Julien Bouley
IPC分类号： A61K39/35 , C12P21/00 , C07K14/435
CPC分类号： C07K14/43531 , C07H21/02 , C07H21/04 , C12N1/00 , C12N1/16 , C12N1/20 , C12N15/00 , C12N15/09 , C12P21/00
摘要： The present invention concerns a method for producing a recombinant Dermatophagoides pteronyssinus 2 protein (rDer p 2), comprising the steps of cultivating a Pichia pastoris yeast strain previously transformed with a rDer p 2 coding sequence, and isolating the rDer p 2 protein from said Pichia pastoris yeast strain. The invention also relates to compositions and kits comprising the rDer p 2 protein for therapeutic or diagnostic use.
摘要翻译： 本发明涉及一种生产重组体Dermatophagoides pteronyssinus 2蛋白（rDer p2）的方法，包括以下步骤：培养先前用rDer p2编码序列转化的巴斯德毕赤酵母菌株，并从所述毕赤酵母中分离rDer p2蛋白 巴斯德毕赤酵母菌株。 本发明还涉及包含用于治疗或诊断用途的rDer p2蛋白的组合物和试剂盒。
-
7.发明授权Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route 有权IgG1免疫球蛋白和/或CD32受体的配体用于通过粘膜途径治疗炎性疾病和表现公开(公告)号：US09187568B2
公开(公告)日：2015-11-17
申请号：US13319074
申请日：2010-05-07
CPC分类号： C07K16/4291 , A61K2039/505 , A61K2039/542 , A61K2039/545 , C07K2317/41 , C07K2317/76
摘要： The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.
摘要翻译： 本发明涉及IgG1型免疫球蛋白和更通常的CD32受体的配体用于治疗炎性疾病和表现，特别是过敏和自身免疫性疾病，特别是过敏性哮喘的治疗的用途， 免疫球蛋白和配体通过粘膜途径施用，特别是通过舌下途径施用。
-
8.发明申请USE OF IGG1 IMMUNOGLOBULINS AND/OR LIGANDS OF THE CD32 RECEPTOR FOR TREATING INFLAMMATORY DISEASES AND MANIFESTATIONS VIA THE MUCOSAL ROUTE 有权使用IGG1免疫球蛋白和/或CD32受体的配体，用于治疗炎性疾病和通过胶原路线的排卵公开(公告)号：US20120171198A1
公开(公告)日：2012-07-05
申请号：US13319074
申请日：2010-05-07
IPC分类号： A61K39/395 , A61P11/06 , A61P37/00 , A61P29/00 , A61P37/08
CPC分类号： C07K16/4291 , A61K2039/505 , A61K2039/542 , A61K2039/545 , C07K2317/41 , C07K2317/76
摘要： The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.
摘要翻译： 本发明涉及IgG1型免疫球蛋白和更通常的CD32受体的配体用于治疗炎性疾病和表现，特别是过敏和自身免疫性疾病，特别是过敏性哮喘的治疗的用途， 免疫球蛋白和配体通过粘膜途径施用，特别是通过舌下途径施用。
-
公开(公告)号：US08632993B2
公开(公告)日：2014-01-21
申请号：US13318213
申请日：2010-04-30
申请人： Philippe Moingeon , Thierry Batard , Emmanuel Nony
发明人： Philippe Moingeon , Thierry Batard , Emmanuel Nony
CPC分类号： G01N33/6848 , G01N2333/415
摘要： The present invention relates to the use of at least one peptide comprising or consisting of a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, for determining the presence of extracts from at least one grass species in a composition.
摘要翻译： 本发明涉及至少一种肽的用途，所述肽包含选自SEQ ID NO：1，SEQ ID NO：2，SEQ ID NO：3，SEQ ID NO：4和SEQ ID NO： 用于确定组合物中至少一种草种的提取物的存在的NO.5。
-
公开(公告)号：US20120171710A1
公开(公告)日：2012-07-05
申请号：US13318213
申请日：2010-04-30
申请人： Philippe Moingeon , Thierry Batard , Emmanuel Nony
发明人： Philippe Moingeon , Thierry Batard , Emmanuel Nony
IPC分类号： G01N27/62 , C07K14/415 , C07K7/06 , C07K7/08
CPC分类号： G01N33/6848 , G01N2333/415
摘要： The present invention relates to the use of at least one peptide comprising or consisting of a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, for determining the presence of extracts from at least one grass species in a composition.
摘要翻译： 本发明涉及至少一种肽的用途，所述肽包含选自SEQ ID NO：1，SEQ ID NO：2，SEQ ID NO：3，SEQ ID NO：4和SEQ ID NO： 用于确定组合物中至少一种草种的提取物的存在的NO.5。
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.026 秒)
